Search Within

Matthew David Hellmann

Formats
  1. Meeting Abstract (210)
  2. Journal Article (187)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (412)
  2. Solid Tumor Oncology Division (412)
  3. Thoracic Oncology (412)
  4. GSK Faculty (140)
  5. Department of Pathology and Laboratory Medicine (112)
  6. Weinberg Fellows (103)

More Groups

People
  1. Hira Rizvi (97)
  2. Mark Kris (71)
  3. Jamie Chaft (68)
  4. Charles Rudin (67)
  5. Jedd Wolchok (53)
  6. Gregory Riely (49)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (34)
  5. 2021 (40)
  6. 2020 (55)

More Years

Publications
  1. Journal of Clinical Oncology (91)
  2. Journal of Thoracic Oncology (58)
  3. Annals of Oncology (49)
  4. Journal for ImmunoTherapy of Cancer (30)
  5. Cancer Research (24)
  6. Clinical Cancer Research (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (96)
  2. Elsevier Inc. (75)
  3. American Association for Cancer Research (57)
  4. Oxford University Press (53)
  5. Biomed Central Ltd (30)
  6. Nature Publishing Group (21)

More Publishers

Results (412)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma Is affected by KRAS mutation status
    Journal Article

    Ricciuti, B.; Arbour, K. C.; Lin, J. J.; Vajdi, A.; Vokes, N.; Hong, L.; Zhang, J.; Tolstorukov, M. Y.; Li, Y. Y.; Spurr, L. F.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • First-line immunotherapy for non-small-cell lung cancer
    Review

    Reck, M.; Remon, J.; Hellmann, M. D.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 checkmate 227 part 1 trial
    Journal Article

    Paz-Ares, L. G.; Ramalingam, S. S.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab
    Journal Article

    Thor, M.; Shepherd, A. F.; Preeshagul, I.; Offin, M.; Gelblum, D. Y.; Wu, A. J.; Apte, A.; Simone, C. B. 2nd; Hellmann, M. D.; Rimner, A.; more...
    Radiotherapy and Oncology (2022)

    Fulltext@MSK | Save
  • Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types
    Journal Article

    Chhibber, A.; Huang, L.; Zhang, H.; Xu, J.; Cristescu, R.; Liu, X.; Mehrotra, D. V.; Shen, J.; Shaw, P. M.; Hellmann, M. D.; more...
    Immunity (2022)

    Fulltext@MSK | Save
  • TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion
    Journal Article

    Shakiba, M.; Zumbo, P.; Espinosa-Carrasco, G.; Menocal, L.; Dündar, F.; Carson, S. E.; Bruno, E. M.; Sanchez-Rivera, F. J.; Lowe, S. W.; Camara, S.; more...
    Journal of Experimental Medicine (2022)

    Fulltext@MSK | Save
  • Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer
    Editorial

    Chow, A.; Hellmann, M. D.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M.; Cho, B.; Juergens, R.; Cheng, Y.; de Castro, G.; Erman, M.; Bauman, J.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Keynote-495/keyimpact: Interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (Nsclc)
    Meeting Abstract

    Gutierrez, M.; Lam, W. S.; Hellmann, M.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
    Meeting Abstract

    Zhang, J.; Caushi, J.; Oliveira, G.; Zhang, B.; Ji, Z.; Naidoo, J.; Marrone, K.; Taube, J.; Hellmann, M.; Brahmer, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save